Rituximab vs other disease‐modifying treatments
Comparison intervention · relapsing multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
13 questions · 13 findings · 1 reviews
No studies found 3 · 23.1%GRADE not reported 0 · 0%Very low 1 · 7.7%Low 7 · 53.8%Moderate 2 · 15.4%High 0 · 0%
Rituximab vs placebo
Quality of life · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Rituximab vs placebo
Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
- OR 1.14 [0.75, 1.73]1 study · 439 participantsLow
Rituximab vs placebo
Cancer · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
- OR 0.5 [0.07, 3.59]1 study · 439 participantsLow
Rituximab vs placebo
Mortality measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
- OR 0.25 [0.02, 2.77]1 study · 439 participantsLow
Rituximab vs other disease‐modifying treatments
— · relapsing multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Rituximab vs other disease‐modifying treatments
Interferon beta or glatiramer acetate · relapsing multiple sclerosis
Rituximab as 'first choice' probably leads to lower interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).
1 finding from 1 review
- HR 0.14 [0.05, 0.39]335 participantsModerate
Rituximab vs other disease‐modifying treatments
Dimethyl fumarate · relapsing multiple sclerosis
Rituximab as 'first choice' showed no clear difference in dimethyl fumarate compared with other disease‐modifying treatments (low certainty).
1 finding from 1 review
- HR 0.29 [0.08, 1]206 participantsLow
Rituximab vs other disease‐modifying treatments
Natalizumab · relapsing multiple sclerosis
Rituximab as 'first choice' showed no clear difference in natalizumab compared with other disease‐modifying treatments (low certainty).
1 finding from 1 review
- HR 0.24 [0.06, 1]170 participantsLow
Rituximab vs other disease‐modifying treatments
Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'first choice' changes fingolimod compared with other disease‐modifying treatments (very low certainty).
1 finding from 1 review
- HR 0.26 [0.04, 1.69]137 participantsVery low
Rituximab vs placebo
Disability worsening · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty).
1 finding from 1 review
- OR 0.71 [0.45, 1.11]1 study · 439 participantsModerate
Rituximab vs placebo
Clinical relapse · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in relapse measured by clinical assessment over 24 months compared with placebo (low certainty).
1 finding from 1 review
- OR 0.6 [0.18, 1.99]1 study · 439 participantsLow
Rituximab vs placebo
Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
- OR 1.25 [0.71, 2.2]1 study · 439 participantsLow